MohammadJahanzebMD

PubMed

• International experts consensus on optimal central vascular access device selection and management for patients with cancer.
  Mohammad Jahanzeb, Ching-Yang Wu, Howard Lim, Kei Muro, Lichao Xu
  The Journal of Vascular Access. 2024-12-02
• A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive...
  Jessica Mezzanotte-Sharpe, Anne ONeill, Ingrid A Mayer, Carlos L Arteaga, Ximing J Yang
  Breast Cancer Research and Treatment. 2024-09-01
• A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive...
  Jessica Mezzanotte-Sharpe, Anne ONeill, Ingrid A Mayer, Carlos L Arteaga, Ximing J Yang
  Research Square. 2024-04-29

Journal Articles

• “SWOG S0802: A Randomized Phase II Trial of Weekly Topotecan with and without Ziv-aflibercept in Patients with Platinum-Treated Small Cell Lung Cancer”  
  Allen J, Moon J, Redman M, Gadgeel S, Kelly K, Mack P, Saba H, Mohamed M, Jahanzeb M, and David R Gandara, Journal of Clinical Oncology/ J Clin Oncol., 1/7/2014
• “Adverse Event Management in Patients With Advanced Cancer Receiving Oral Everolimus: Focus on Breast Cancer”  
  Aapro M, Andre F, Blackwell K, Calvo E, Jahanzeb M, Papazisis K, Porta C, Pritchard K, Ravaud A, Annals of Oncology, 1/1/2014
• “Malignant Pleural Mesothelioma”  
  Ettinger DS, Akerley, Jahanzeb M, et.al., JNatl Compr Canc Netw., 1/1/2012
• “Non-Small Lung Cancer: “Clinical Practice Guidelines in Oncology”  
  Ettinger DS, Akerley W, Borhhaei H, Chang AC, Cheney RT, Chirieac LR, D’Amico TA, Demmy TL, Ganti AK, Govindan, R, Grannis, Jr. FW, Horn L, Jahan TM, Jahanzeb M, Kessi..., J National Comprehensive Cancer Network, 1/1/2012
• “Blockade of the HER family of Receptors in the Treatment of HER2-Positive Metastatic Breast Cancer” Clinical Breast Cancer, Vol 12, No 1, 19-29 ©Mahtani R, Khan R, Ja...  
  Sachdev J, Jahanzeb M, Clin Lung Cancer, 1/1/2011
• “Neoadjuvant bevacizumab with weekly nanoparticle albumin bound (nab)-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple negativ...  
  Snider JN, Allen JW, Young R, Schwartzberg L, Javed Y, Jahanzeb M, Sachdev JC, J Clin Oncol, 1/15/2010
• “Does race affect outcomes in triple negative breast cancer?"  
  Sachdev JC, Ahmed S, Mirza MM, Farooq A, Kronish L, Jahanzeb M, Breast Cancer, 1/7/2010
• “Modification and Implementation of NCCN Guidelines on Breast Cancer in the Middle East and North Africa Region”  
  Abulkhair O, Saghi L, Saadedin A, Elzahwary H, Siddiqui N, Al Saleh M, Geara F, Birido N, Al-Eissa N, Sukhun SA, Abdulkareem H, Ayoub MM, Deirawan F, Fayaz S, Kandil A..., J Natl Compr Canc Netw., 1/1/2010
• “Anastozole versus Exemestane in patients with postmenopausal breast cancer and visceral metastases”  
  Schreiber A, Sachdev J, Jahanzeb M, Clinical Medicine Reviews in Oncology, 1/1/2010
• “Bisphosponates in lung cancer: more than a palliative therapy?”  
  Jahanzeb M, et al., Seminars in Oncology, 1/1/2010
• “Bisphosphonates as Anticancer Therapy for Early Breast Cancer”  
  Mahtani R, Jahanzeb M, Clinical Breast Cancer, 1/1/2010
• “NCCN Clinical Practice Guidelines in Oncology, Breast Cancer”  
  Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, hudis CA, Jahanz..., National Comprehensive Cancer Network, 1/1/2010
• “NCCN Clinical Practice Guidelines in Oncology, Non-Small Cell Lung Cancer”  
  Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney R, Chirieac LR, D’Amico TA, Demmy TL, Govindan R, Grannis FW, Jahan T, Jahanzeb M, et al., National Comprehensive Cancer Network, 1/1/2010
• “Bisphosphonates in lung cancer: more than a palliative therapy?”  
  Jahanzeb M, et al., Seminars in Oncology, 1/1/2010
• “Non-small cell lung cancer”  
  Ettinger D, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D’Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, JahanT, Jahanzeb M, et al., Journal of the National Comprehensive Cancer Network, 1/1/2010
• “Bisphophonates as anticancer therapy for early breast cancer”  
  Mahtani R, Jahanzeb M, Clinical Breast Cancer, 1/1/2010
• “NCCN Oncology Risk Evaluation and Mitigation Strategies White Paper: “Recommendations for Stakeholders”  
  Johnson PE, Dahlman G, Eng K, Garg R, Gottlieb S, Hoffman J, Howell P, Jahanzeb M, et al., Journal of the National Comprehensive Cancer Network, 1/1/2010
• “Modification and Implementation of NCCN Guidelines on Non-Small Cell Lung Cancer in the Middle East and North Africa Region"  
  Jazieh AR, Bamefleh H, Demirkazik A, Gaafar RM, Geara FB, Javaid M, Khader J, Omar W, Saadeddin A, Sabe HA, Shadmehr MB, El Sherif A, Uddin N, Jahanzeb M, Ettinger D; ..., J Natl Compr Canc Netw., 1/1/2010
• NCCN Oncology Risk Evaluation and Mitigation Strategies (REMS) Work Group  
  Johnson PE, Dahlman G, Eng K, Garg R, Gottlieb S, Hoffman JM, Howell P, Jahanzeb M, Johnson S, Mackler E, Rubino M, Sarokhan B, Marc Stewart F, Tyler T, Vose, JM, Wein..., J Natl Compr Canc Netw., 1/1/2010
• “The Abu Dhabi Declaration: Adapted Application of NCCN Clinical Practice Guidelines in Oncology in the Middle East and North Africa Region”  
  Jazieh A, Azim H, McClure J, Jahanzeb M, Journal of the National. Comprehensive Cancer Network, 1/1/2010
• “The process of NCCN Guidelines adaptation to the Middle East and North Africa Region”  
  Jazieh AR, Azim HA, McClure J, Jahanzeb M, J Natl Compr Canc Netw., 1/1/2010
• “Modification and Implementation of NCCN Guidelines on Breast Cancer in the Middle East and North African Region"  
  Abulkhair O, Saghir N, Sedky L, Saadedin A, Elzahwary H, Saddiqui N, Al Saleh M, Geara F, Birido N, Al Eissa N, Sukhun SA, Abdulkareem H, Ayoub MM, Deirawan F, Fayaz S..., J Natl Compr Canc Netw., 1/1/2010
• “The Process of NCCN Guidelines Adaptation to the Middle East and North African Region”  
  Jazieh AR, Azim HA, McClure J, Jahanzeb M, J Natl Compr Canc Netw., 1/1/2010
• “Modification and Implementation of NCCN Guidelines on Non-Small Lung Cancer in the Middle East and North Africa Region”  
  Jazieh AR, Bamefleh H, Demirkazik A, Gaafar RM, Javaid M, Khader J, Khodadad K, Omar W, Saadeddin A, Sabe HA, Shadmehr MB, El Sherif A, Uddin N, Jahanzeb M, Ettinger D..., J National Comprehensive cancer Network, 1/1/2010
• “The Abu Dhabi Declaration: Adapted Application of NCCN Clinical Practice Guidelines in Oncology in the Middle East and North Africa Region”  
  Jazieh A, Azim H, McClure J, Jahanzeb M, Journal of the National Comprehensive Cancer Network, 1/1/2010
• Join now to see all

Books/Book Chapters

• “Lung Cancer: A Practical Guide” 
  Page 111 - 123Raez L, Silva O, Jahanzeb MElsevier Limited2008
• NCCN Lung Cancer Treatment Guidelines for Patients, Version II 
  Jahanzeb M, et.al.JNCCN2004
• The Washington Manual of Oncology 
  Chapter: "Breast Cancer" 
  Page 112 - 142Chantler ML, and Jahanzeb MLippincott Williams & Wilkins2002
• The Chemotherapy Source Book 
  Chapter: “Chemotherapy of Lung Cancer” 
  Page 1103 - 1123Jahanzeb M and Ihde DCEditors: Perry MC.Williams & Wilkins, Philadelphia, PAEdition 2nd,1995
• Join now to see all

Abstracts/Posters

• A Randomized, Phase II Trial of Weekly Topotecan With and Without Ziv-Aflibercept in Patients With Platinum-Treated Small-Cell Lung Cancer.
  J, Redman M, Gadgeel SM, Kelly K, Mack PC, Saba HM, Mohamed MK, Jahanzeb M, Gandara DR, Southwest Oncology Allen JW, Moon Group S0802, J Clin Oncol., 1/7/2014
• "The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic ...
  Tripathy D1, Rugo HS, Kaufman PA, Swain S, O'Shaughnessy J, Jahanzeb M, Mason G, Beattie M, Yoo B, Lai C, Masaquel A, Hurvitz S., 1/2/2014
• Pathway activation mapping metastatic breast cancer identifies potential organ-specific signatures: implications for patient stratification to targeted treatment.
  Pierobon M, Anthony SP, Reeder A, Nicholas Robert, D. Northfelt, M. Jahanzeb, Vocila L, Wulfkuhle J, Dunetz B, Liotta L, Petricoin E. F., San Antonio Breast Cancer Symposium, 1/1/2014
• “Increasing proportion of de novo compared with recurrent HER2-positive metastatic breast cancer: early results from the Systemic Therapies for HER2-Positive Metastati...
  Tripathy D, Brufsky A, Cobleigh M, Jahanzeb M, Kaufman P, Mason G, Mayer M, O’Shaughnessy J, Rugo S. H, Swain. M S, Yardley A. D, Beattie M, Yoo B, Hurvitz S, SABCS, 1/1/2014
• Effectiveness and safety of post-induction phase bevacizumab treatment for patients with non small-cell lung cancer: results from the ARIES observational cohort study.
  MP Kosty,1 A Wozniak,2 M Jahanzeb,3 L Leon,4 S. Fish,4 S. Hazard,4 TJ Lynch Jr5, 1/1/2014
• “Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer.”
  Aapro M1, Andre F, Blackwell K, Calvo E, Jahanzeb M, Papazisis K, Porta C, Pritchard K, Ravaud A, Ann Oncol., 1/1/2014
• Clinical impact of internet-based tools to help guide therapeutic decisions for metastatic breast cancer (MBC).
  KL Obholz, KL Blackwell, S Glück, M Jahanzeb, KD Miller, NJ Robert, AD Bowser, J Mortimer, and RW Carlson, Cancer Research, 1/15/2013
• “Phase 2 Double-Blind, Placebo-Controlled Doublet in Subjects with Previously Untreated Folate Receptor Alpa (FRA) Expressing Non Small Cell Lung Cancer (NSCLC)”.
  Maltzman JD, Fatato P, Hoffman K, Dougherty K, O’Shannessy D, Somers EB, Cobo M, Felip E, Jahanzeb M; Morphotek, Exton, PA; Hospital Regional Universitario Carlos Hay..., Poster Presentation, IASLC, 1/1/2013
• “High pathologic complete response (pCR) with weekly nanoparticle albumin bound (nab-P) + carboplatin (C) followed by doxorubicin plus cyclophoshamide (AC) with concu...
  Snider JN, Sachdev JC, Allen JW, Schwartzberg LS, Young RR, Javed AY, Yunus F, Verrier CS, Jahanzeb M; University of Tennessee, Memphis, TN; Virginia G. Piper Cancer C..., Proceedings of ASCO, 1/1/2013
• “Neoadjuvant bevacizumab with weekly nanoparticle albumin bound (nab)-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple negativ...
  Sachdev JC, Kronish LE, West S, Schwartzberg L, Jahanzeb M, ASCO 2010, 1/15/2012
• "Neoadjuvant Bevacizumab with Weekly Nanoparticle Albumin Bound (nab)-Paclitaxel Plus Carboplatin Followed by Doxorubicin Plus Cyclophosphamide (AC) for Triple Negativ...
  Snider JN, Allen JW, Young R, Schwartzberg L, Javed Y, Jahanzeb M, Sachdev JC, SABCS, 1/1/2012
• “Non-small cell lung cancer.”
  Ettinger D, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D’Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, JahanT, Jahanzeb M, et al., J Natl Comp Canc Netw., 1/1/2012
• Neoadjuvant bevacizumab with weekly nab-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple-negative breast cancer.
  Snider, J Young,R Schwartzberg, L….. Jahanzeb, M and Sachdev J, PASCO, 1/1/2012
• “Cumulative Exposure to Bevacizumab (BV) After Induction Therapy (tx) Correlates with Increased Survival in Patients (pts) with Non-small Cell Lung Cancer (NSCLC)”
  Wozniak A, Jahanzeb M, Lynch T, Stockholm Congress/ECCO/ESMO Poster Presentation, 1/1/2011
• “Clinical Outcomes for Bevacizumab (BV)-treated Elderly Patients with Non-small Cell Lung Cancer (NSCLC): Results from the ARIES Observational Cohort Study (OCS)”
  Kosty M, Jahanzeb M, Garst J, Spigel D, Leon L, Wendlberger S, Schnurr J, Photowala H, Stockholm Congress/ECCO/ESMO Poster Presentation, 1/1/2011
• “Use of Bevacizumab (BV) After Induction Therapy is Associated with Survival Benefit in Patients (pts) with Non-small Cell Lung Cancer (NSCLC) in the ARIES Observation...
  Brahmer J, Jahanzeb M, Priya K, Robles R, Wozniak A, Lynch T, Stockholm Congress/ECCO/ESMO Poster Presentation, 1/1/2011
• Reducing the Risk for Breast Cancer Recurrence After Completion of TamoxifenTreatment in Postmenopausal Women.
  Jahanzeb M, Clinical Therapeutics, 1/1/2007
• A multicenter phase II trial of carboplatin, vinorelbine, and trastuzumab in previously untreated patients with HER2 positive metastatic breast cancer.
  Sachdev J, Jahanzeb M, SABCS, 1/1/2007
• Empiric dose reduction of pegfilgrastin in breast cancer patients receiving cytotoxic chemotherapy.
  Waheed S, Jahanzeb M, SABCS, 1/1/2007
• Dose dense neoadjuvant treatment of women with breast cancer utilizing docetaxel, vinorelbine and trastuzumab with growth factor support.
  Jahanzeb M, Limentani SA, et.al, Selected for poster presentation at American Society of Clinical Oncology Annual Meeting, 1/1/2005
• A practice-based, voluntary program for promoting excellence in cancer care: A Pilot study of feasibility, cost and preliminary results.
  Desch CE, Eisenberg D, Gesme D, Jacobson J, Jahanzeb M, et.al., American Society of Clinical Oncology Annual Meeting, 1/1/2004
• Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide for stage III breast cancer: Clinical response and long-tern survival.
  Swain, S.M., Jahanzeb, M. Erban, J.K., Limentani, S.A., Hardikar, S., Tsai, D.T., Olsen, S.R., Gradishar, W.J., National Cancer Institute, Bethesda, MD; Comprehensive ..., American Society of Clinical Oncology, 1/1/2003
• Low utility of bone marrow biopsy and aspirate for ruling out malignancy as a cause for FUO in HIV patients.
  Peyton, J.D., Flax, S., Jahanzeb, M., University of Tennessee Cancer Institute, Memphis, TN; University of Tennessee, Memphis, TN, American Society of Clinical Oncology, 1/1/2003
• Docetaxel and cisplatin as induction therapy for stage IIIA (N2) non-small cell lung cancer (NSCLC).
  Dragnev, K.H., Clamon, G., Raez, L. Jahanzeb, M., et.al., American Society of Clinical Oncology, 1/1/2003
• Blumenthal Cancer Center, Charlotte, NC: Dose dense neoadjuvant treatment of women with beast cancer utilizing docetaxel and vinorelbine with growth factor support.
  Limentani, S.A., Brufsky, A.M., John, E., Jahanzeb, M, Lewis, D., Carolinas Hem-Onc Associates and the Blumenthal Cancer Center, Charlotte, NC; Maee-Women’s Hospital, ..., American Society of Clinical Oncology, 1/1/2003
• Join now to see all

Lectures

• 9th Annual New Orleans Summer Cancer Meeting 
  New Orleans, LA - 1/1/2014
• “Lung Cancer” 
  Deland, FL - 1/1/2014
• “Targeted Therapy for Lung Cancer: A Case Based Presentation” 
  Jacksonville, FL - 1/1/2014
• “Evaluation of Genomic Platforms in Invasive Breast Cancer: A Review of Clinical Validation Evidence and Two Head-to-Head Clinical Utility Studies”. 
  1/23/2013
• “Management of Bone Metastasis in Breast Cancer”. 
  Goiania, Brazil - 1/23/2013
• “Blockades and Barricades in the HER Family of Receptors” 
  Miami, FL - 1/1/2013
• “NCCN Overview: Guidelines Development and Implementation in the United States”. 
  Namibia, South Africa - 1/26/2012
• “NCCN International Initiatives" 
  Namibia, South Africa - 1/26/2012
• “Challenges in Adaptation and Adoption of the NCCN Guidelines” 
  Moscow, Russia - 1/19/2012
• “NCCN” Guidelines Process: International Adaptations”. 
  Salvador, Brazil - 1/10/2012
• “Neoadjuvant Chemotherapy in Breast Cancer”. 
  Salvador, Brazil - 1/10/2012
• "NCCN Guidelines: The Process of Guideline Development”. 
  Lahore, Pakistan - 1/8/2012
• “Towards More Personalized Therapy for Non-Small Lung Carcinoma" 
  Lahore, Pakistan - 1/8/2012
• “Estimating Risk of Recurrence in Early Stage Breast Cancer”. 
  Lahore, Pakistan - 1/8/2012
• “Challenges and Opportunities in the International Adaptation of the NCCN Guidelines” 
  Doha, Qatar - 1/1/2012
• San Antonio Breast Cancer Conference Symposium 
  San Antonio, TX - 1/1/2012
• “Consideration in Curative Systemic Therapy of Early Breast Cancer”. 
  Memphis, TN - 1/1/2012
• “Evolution of HER2 Directed Therapy in Breast Cancer”. 
  Memphis, TN - 1/1/2012
• “Options in the Treatment of Metastatic Breast Cancer” 
  Phoenix, AZ - 1/1/2012
• “Updates in the Treatment of Metastatic Breast Cancer” 
  Jamaica, NY - 1/1/2012
• “Breast Cancer Academic Advisory Board” 
  San Francisco, CA - 1/1/2012
• “Economic Implications of Cancer and Cancer Treatment” “Impact of Guidelines in Clinical Practice” 
  Gramado, Brazil - 1/1/2011
• “Breast Conservation after Neoadjuvant Therapy” 
  Goiania, Brazil - 1/1/2011
• “Which Patient Should be Offered Neoadjuvant Therapy” 
  Goiania, Brazil - 1/1/2011
• “The State of the Art on the Treatment of HER2 Positive Breast Cancer Patients” 
  Goiania, Brazil - 1/1/2011
• Join now to see all

Other

• “Focus on Cytotoxic Therapy” 
  Jahanzeb M, Yardley D, Recent Progress in Metastatic Breast Cancer, Physicians’ Education Resource
  1/1/2013
• “Avastin Breast / Herceptin Breast” (National Audio/Web Conference) 
  Jahanzeb M
  1/1/2009
• “Current Debates in the Treatment of HER 2+ Metastatic Breast Cancer” (National Audio/Web Conference) 
  Jahanzeb M
  1/1/2008
• “Managing Side Effects of Cancer Treatments” 
  Jahanzeb M, Caring4Cancer
  1/1/2007
• "The New Targeted Therapies: What You Should Know” 
  Jahanzeb M, Caring4Cancer
  1/1/2007
• “Sexuality and Cancer” 
  Jahanzeb M, Caring4Cancer
  1/1/2007
• “Help Your Health Care Team Help You” 
  Jahanzeb M, Caring4Cancer
  1/1/2007
• “A Patient with Bilateral Breast Cancer Treated with Neoadjuvant and Adjuvant Trastuzumab” 
  Sachdev J, Jahanzeb M, Case Studies in Breast Cancer
  1/1/2007
• “Advances in the Treatment of Breast Cancer” 
  Sachdev J, Jahanzeb M, The Memphis Medical Society Quarterly
  1/1/2007
• “Trastuzumab: The Foundation of Care for HER2-positive Breast Cancer” (it is an insert within the regular issue and is numbered separately). 
  Jahanzeb M, Oncology Nursing News
  1/1/2007
• "New Developments in the Management of Advanced Breast Cancer” (National Audio/Web Conference) 
  Jahanzeb M
  1/1/2007
• “Clinical Review: Trastuzumab: the foundation of care for HER2-positive breast cancer.” (it is an insert within the regular issue and is numbered separately). 
  Jahanzeb M, Oncology Nursing News
  1/1/2007
• “Management of a Patient with HER2-Overexpressing Infiltrating Ductal Carcinoma with Ductal Carcinoma In Situ” 
  Jahanzeb M, Leyland-Jones B, Oncology Consultations
  1/1/2006
• “Controversies Surrounding the Optimal Use of Chemotherapy in Breast Cancer” (National Audio/Web Conference) 
  Jahanzeb M
  1/1/2006
• “How to Choose Therapy" 
  Jahanzeb M, Galleshaw J, Caring4Cancer
  1/1/2006
• "Adjuvant Chemotherapeutic Treatment of Node-Positive, Hormone-Negative Breast Cancer” 
  Jahanzeb M, Vogel C, Oncology Consultations
  1/1/2006
• “After Diagnosis of Non-Small Cell Lung Cancer, The Real Workup Begins” 
  Rosenthal, M, Jahanzeb, M, Hem/Onc Today
  1/1/2005
• “An Overview of Anti-HER2 Therapy in Combination with Chemotherapy in Metastatic Breast Cancer” 
  Jahanzeb M, Biological Therapy of Breast Cancer
  1/1/2004
• “Treatment of HER2-Overexpressing Metastatic Breast Cancer with Chemotherapy and Anti-HER2 Monoclonal Antibody” 
  Jahanzeb M, Human Epidermal Growth Factor Receptors in Oncology
  1/1/2004
• “A Patient With HER2 Positive Metastatic Breast Carcinoma Treated with Trastuzumab Based Therapy” 
  Aslam R, Jahanzeb M, Physicians’ Education Resource
  1/1/2004
• “Targeted Therapies for Advanced Breast Cancer” (National Audio/Web Conference) 
  Jahanzeb M
  1/1/2002
• “HER2 Testing in Breast Cancer: What is the Best Strategy” (National Audio/Web Conference) 
  Jahanzeb M
  1/1/2002
• “Update in Chemotherapy of Metastatic Breast Cancer” (National Audio/Web Conference) 
  Jahanzeb M
  1/1/2002
• “Off-label use of Herceptin within Managed Care Settings and Hospitals” (National Audio/Web Conference) 
  Jahanzeb M
  1/1/2002
• “Advances in the Management of Metastatic Breast Cancer” (National Audio/Web Conference) 
  Jahanzeb M
  1/1/2001
• Join now to see all